Tumor Biology

, Volume 36, Issue 8, pp 6231–6238 | Cite as

Association between SNPs in Serpin gene family and risk of esophageal squamous cell carcinoma

Research Article

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive cancers in the world. Epidemiological survey studies have verified that the development of ESCC relates to a complex interactive process between multiple genetic susceptibilities and environmental exposure. Serpins are a broadly distributed family of protease inhibitors and have been recognized as tumor suppressors in multiple cancer types. While previous studies have reported that Serpin polymorphisms are associated with tumorigenesis, the genetic and functional single nucleotide polymorphisms (SNP) in these genes appear to be complex and remain to be elucidated. In this study, a total of 500 ESCC cases and 500 matched controls in a Southwest China population were evaluated for six SNPs in the exons of three Serpin genes (SerpinB5, SerpinB2, and SerpinE1). Among the six SNPs, the C allele of rs2289519 and rs2289520 in SerpinB5 showed decreased risk of ESCC and the variants might interact with smoking status. Haplotype analysis showed that the T-G haplotype (corresponding to rs2289519-rs2289520) increased the risk of ESCC, while the C-C haplotype decreased the risk. We also found that SerpinB5 gene mRNA expression was significantly downregulated in ESCC cell lines and patient specimen while there is no change in protein structure with different haplotypes. Our results demonstrated that the expression of SerpinB5 was downregulated in ESCC, and the positive SNPs might be associated with a risk of ESCC development.

Keywords

Esophageal squamous cell carcinoma Single nucleotide polymorphism (SNP) Serpin Association study 

Notes

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (No. 31100936).

Conflicts of interest

None

Supplementary material

13277_2015_3308_MOESM1_ESM.doc (64 kb)
Supplementary Table 1 (DOC 64 kb)
13277_2015_3308_MOESM2_ESM.doc (28 kb)
Supplementary Table 2 (DOC 28 kb)
13277_2015_3308_MOESM3_ESM.doc (38 kb)
Supplementary Table 3 (DOC 37 kb)
13277_2015_3308_MOESM4_ESM.doc (168 kb)
Supplementary Figure 1 (DOC 167 kb)

References

  1. 1.
    Stahl M, Budach W, Meyer HJ, Cervantes A. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v46–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23:233–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X, et al. Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 2013;5:19–26.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001;276:33293–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994;269:15957–60.PubMedGoogle Scholar
  7. 7.
    Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol. 2007;20:570–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, Bianchi M, et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene. 2008;27:2148–58.CrossRefPubMedGoogle Scholar
  9. 9.
    Jing Y, Kovacs K, Kurisetty V, Jiang Z, Tsinoremas N, Merchan JR. Role of plasminogen activator inhibitor-1 in urokinase’s paradoxical in vivo tumor suppressing or promoting effects. Mol Cancer Res. 2012;10:1271–81.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Klein RM, Bernstein D, Higgins SP, Higgins CE, Higgins PJ. Serpine1 expression discriminates site-specific metastasis in human melanoma. Exp Dermatol. 2012;21:551–4.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ozaki K, Nagata M, Suzuki M, Fujiwara T, Miyoshi Y, Ishikawa O, et al. Isolation and characterization of a novel human pancreas-specific gene, pancpin, that is down-regulated in pancreatic cancer cells. Genes Chromosomes Cancer. 1998;22:179–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Takahashi Y, Mimori K, Mori M. Significance of genome-wide association study in cancer. Nihon Geka Gakkai Zasshi. 2012;113:210–4.PubMedGoogle Scholar
  13. 13.
    Wang K, Guo H, Hu H, Xiong G, Guan X, Li J, et al. A functional variation in pre-microrna-196a is associated with susceptibility of esophageal squamous cell carcinoma risk in Chinese Han. Biomarkers. 2010;15:614–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Southam L, Rodriguez-Lopez J, Wilkins JM, Pombo-Suarez M, Snelling S, Gomez-Reino JJ, et al. An snp in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet. 2007;16:2226–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, Egli R, et al. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet. 2008;17:1497–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, et al. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res. 2011;17:7723–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, et al. Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A. 2011;108:13653–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wang K, Li J, Guo H, Xu X, Xiong G, Guan X, et al. Mir-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 2012;33:2147–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang K, Liu B, Li J, Xiong G, Guan X, Yang K, et al. Association between SNPs in P53 binding regions and risk of esophageal squamous cell carcinoma. Int J Biol Markers. 2014;29:e160–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang JM, Xu B, Rao JY, Shen HB, Xue HC, Jiang QW. Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. Eur J Gastroenterol Hepatol. 2007;19:171–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005;65:9582–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Shao LJ, Shi HY, Ayala G, Rowley D, Zhang M. Haploinsufficiency of the maspin tumor suppressor gene leads to hyperplastic lesions in prostate. Cancer Res. 2008;68:5143–51.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bass R, Fernandez AM, Ellis V. Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem. 2002;277:46845–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Abraham S, Zhang W, Greenberg N, Zhang M. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol. 2003;169:1157–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 2002;21:4089–98.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med. 2000;6:196–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, et al. Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer. 2001;95:337–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Shams TM, Samaka RM, Shams ME. Maspin protein expression: a special feature of papillary thyroid carcinoma. J Egypt Natl Canc Inst. 2006;18:274–80.PubMedGoogle Scholar
  30. 30.
    Kim S, Han J, Kim J, Park C. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res. 2004;64:6900–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang Y, Sheng S, Zhang J, Dzinic S, Li S, Fang F, et al. Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC). PLoS One. 2013;8:e63581.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bieche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M, et al. Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br J Cancer. 2003;88:863–70.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Umekita Y, Ohi Y, Sagara Y, Yoshida H. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer. 2002;100:452–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002;8:2924–32.PubMedGoogle Scholar
  35. 35.
    Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21:7435–51.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Medical GeneticsThird Military Medical UniversityChongqingChina
  2. 2.Department of Thoracic and Cardiac Surgery, Southwest HospitalThird Military Medical UniversityChongqingChina

Personalised recommendations